Aids Treatment with Potential ; Uccs Associate Professor Will Research How, Why Vgv-1 Is Effective
Gazette, The; Colorado Springs, Colo. › January 17, 2008
Linked as:
Summary
A small California company has agreed to license medical technology developed by a local biology professor to research a promising treatment for HIV and AIDS.
Under the complex agreement announced last month, Karen Newell, a University of Colorado at Colorado Springs associate biology professor, will spend about a year determining how and why a compound called VGV-1 developed by Azusa-based Viral Genetics Inc. is effective in treating some HIV and AIDS patients.See the full content of this document
Extract
Aids Treatment with Potential ; Uccs Associate Professor Will Research How, Why Vgv-1 Is Effective
If Newell's research is successful, it will help Viral Genetics win U.S. Food and Drug Administration approval to use the compound in U.S. cl...
See the full content of this document
Sponsored links
